Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies-Reference-Cited by-同舟云学术

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies

Published:2021-11 Issue: Volume:157 Page:198-213
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pearson Andrew D.J.^ORCID,Barry Elly^ORCID,Mossé Yael P.,Ligas Franca,Bird Nick,de Rojas Teresa^ORCID,Zimmerman Zachary F.,Wilner Keith^ORCID,Woessmann Willi,Weiner Susan,Weigel Brenda,Venkatramani Rajkumar^ORCID,Valteau Dominique,Trahair Toby,Smith Malcolm,Singh Sonia,Selvaggi Giovanni^ORCID,Scobie Nicole^ORCID,Schleiermacher Gudrun^ORCID,Richardson Nicholas,Park Julie,Nysom Karsten^ORCID,Norga Koen,Merino Margret,McDonough Joe,Matloub Yousif,Marshall Lynley V.,Lowe Eric^ORCID,Lesa Giovanni,Irwin Meredith,Karres Dominik,Gajjar Amar,Doz François,Fox Elizabeth,DuBois Steven G.^ORCID,Donoghue Martha,Casanova Michela,Caron Hubert,Buenger Vickie^ORCID,Bradford Diana,Blanc Patricia,Barone Amy,Reaman Gregory,Vassal Gilles^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference82 articles.

1. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children;Pearson;Eur J Cancer,2019

2. ACCELERATE and European medicines agency paediatric strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients;Pearson;Eur J Cancer,2020

3. Paediatric strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents;Pearson;Eur J Cancer,2020

4. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration;Pearson;Eur J Cancer,2020

5. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology;Hallberg;Nat Rev Cancer,2013

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10

2. Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer;European Journal of Cancer;2024-08

3. Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors;Oncology and Therapy;2024-04-27

4. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma;Nature Communications;2024-04-23

5. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS;European Journal of Cancer;2024-04